Programmed Cell Death in Cancer Progression and Therapy

361 Pages·2007·2.106 MB·English

by  Roya Khosravi-Far, Eileen White (auth.)

Programmed Cell Death in Cancer
Progression and Therapy
ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY
Editorial Board:
NATHAN BACK, State University of New York at Buffalo
IRUN R. COHEN, The Weizmann Institute of Science
ABEL LAJTHA, N.S. Kline Institute for Psychiatric Research
JOHN D. LAMBRIS, University of Pennsylvania
RODOLFO PAOLETTI, University of Milan
Recent Volumes in this Series
Volume 607
EUKARYOTIC MEMBRANES AND CYTOSKELETON: ORIGINS AND EVOLUTION
Edited by Gáspár Jékely
Volumes 608
BREAST CANCER CHEMOSENSITIVITY
Edited by Dihua Yu and Mien-Chie Hung
Volume 609
HOT TOPICS IN INFECTION AND IMMUNITY IN CHILDREN VI
Edited by Adam Finn and Andrew J. Pollard
Volume 610
TARGET THERAPIES IN CANCER
Edited by Francesco Colotta and Alberto Mantovani
Volume 611
PETIDES FOR YOUTH
Edited by Susan Del Valle, Emanuel Escher, and William D. Lubell
Volume 612
RELAXIN AND RELATED PETIDES
Edited by Alexander I. Agoulnik
Volume 613
RECENT ADVANCES INTO RETINAL DEGENERATION
Edited by Joe G. Hollyfield, Matthew M. LaVail, and Robert E. Anderson
Volume 614
OXYGEN TRANSPORT TO TISSUE XXIX
Edited by Kyung A. Kang
Volume 615
PROGRAMMED CELL DEATH IN CANCER PROGRESSION AND THERAPY
Edited by Roya Khosravi-Far and Eileen White
A Continuation Order Plan is available for this series. A continuation order will bring delivery of each
new volume immediately upon publication. Volumes are billed only upon actual shipment. For further
information please contact the publisher.
Roya Khosravi-Far • Eileen White
Programmed Cell Death
in Cancer Progression
and Therapy
Roya Khosravi-Far Eileen White
Harvard Medical School Rutgers University
Boston, MA Piscataway, NJ
USA USA
ISBN 978-1-4020-6553-8 e-ISBN 978-1-4020-6554-5
Library of Congress Control Number: 2007937291
© 2008 Springer Science + Business Media B.V.
No part of this work may be reproduced, stored in a retrieval system, or transmitted in any form or by any
means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written
p ermission from the Publisher, with the exception of any material supplied specifically for the purpose
of being entered and executed on a computer system, for exclusive use by the purchaser of the work.
Printed on acid-free paper.
9 8 7 6 5 4 3 2 1
springer.com
Dedication
We dedicate this book to three deserving groups. First, our families for their support
and encouragement, Simin, Ghasem, Reza and Ali Khosravi-Far, and Greg, Jason and
Melissa Diamond. Second, to our students, fellows and assistants, who with their hard
work pave the road to discovery. Last but not least, to anyone who has been touched
by cancer, as they are our motivation for this work and for our research.
Contents
Foreword. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ix
Contributors. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . xi
Chapter 1 Cell Death: History and Future . . . . . . . . . . . . . . . . . . . . . . . . 1
Zahra Zakeri and Richard A. Lockshin
Chapter 2 Caspase Mechanisms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
Guy S. Salvesen and Stefan J. Riedl
Chapter 3 The Mitochondrial Death Pathway. . . . . . . . . . . . . . . . . . . . . . 25
Anas Chalah and Roya Khosravi-Far
Chapter 4 Apoptotic Pathways in Tumor Progression
and Therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
Armelle Melet, Keli Song, Octavian Bucur, Zainab Jagani,
Alexandra R. Grassian, and Roya Khosravi-Far
Chapter 5 Therapeutic Targeting of Death Pathways in Cancer:
Mechanisms for Activating Cell Death in Cancer Cells. . . . . 81
Ting-Ting Tan and Eileen White
Chapter 6 Overcoming Resistance to Apoptosis in
Cancer Therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 105
Peter Hersey, Xu Dong Zhang, and Nizar Mhaidat
Chapter 7 Trail Receptors: Targets for Cancer Therapy. . . . . . . . . . . . . 127
Robin C. Humphreys and Wendy Halpern
Chapter 8 Rational Design of Therapeutics Targeting the BCL-2
Family: Are Some Cancer Cells Primed for Death
but Waiting for a Final Push?. . . . . . . . . . . . . . . . . . . . . . . . . . 159
Victoria Del Gaizo Moore and Anthony Letai
vii
viii Contents
Chapter 9 Autophagy and Tumor Suppression: Recent Advances
in Understanding the Link between Autophagic
Cell Death Pathways and Tumor Development. . . . . . . . . . . 177
Shani Bialik and Adi Kimchi
Chapter 10 Regulation of Programmed Cell Death
by the P53 Pathway . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 201
Kageaki Kuribayashi and Wafik S. El-Deiry
Chapter 11 Regulation of Programmed Cell Death by NF-kB
and its Role in Tumorigenesis and Therapy . . . . . . . . . . . . . 223
Yongjun Fan, Jui Dutta, Nupur Gupta, Gaofeng Fan,
and Céline Gélinas
Chapter 12 Targeting Proteasomes as Therapy in Multiple
Myeloma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 251
Dharminder Chauhan, Teru Hideshima,
and Kenneth C. Anderson
Chapter 13 Histone Deacetylase Inhibitors: Mechanisms
and Clinical Significance in Cancer: HDAC
Inhibitor-Induced Apoptosis . . . . . . . . . . . . . . . . . . . . . . . . . . 261
Sharmila Shankar and Rakesh K. Srivastava
Chapter 14 RNA Interference and Cancer: Endogenous
Pathways and Therapeutic Approaches. . . . . . . . . . . . . . . . . 299
Derek M. Dykxhoorn, Dipanjan Chowdhury,
and Judy Lieberman
Chapter 15 Cancer Stem Cells and Impaired Apoptosis . . . . . . . . . . . . . 331
Zainab Jagani and Roya Khosravi-Far
Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 345
Foreword
Apoptosis is a tightly regulated cell-suicide program that plays an essential role in
development and maintenance of tissue homeostasis by eliminating unnecessary or
harmful cells. Impairment of this native defense mechanism of the cell promotes
uncontrolled growth and frequently confers chemoresistance to tumor cells. Substantial
progress has been made in the elucidation of several of the underlying mechanisms
of apoptotic signaling and their dysregulation in cancer. These advances have facili-
tated the identification of new drug targets for promising apoptosis-inducing
therapeutic strategies. Several of the novel therapeutic agents directed against these
targets demonstrate enhanced apoptotic killing and sensitize resistant cancer cells
to antineoplastic agents. As a number of these agents have entered the clinic and
more are in the pipeline, this is an exciting time for reaping the benefits of years of
basic science discoveries through their translation into cancer therapies.
In this book, the regulation of apoptotic signaling in normal cells and the means
by which this protective response is suppressed in cancer cells will be discussed. In
addition, the novel apoptosis-inducing therapeutic strategies will be summarized.
We hope that this book will be a useful source for scientists and clinicians.
Acknowledgments
We acknowledge the editorial support of Susan Glueck, Jessica Platti, Lydia Gregg
and Tami Sharkey. We also recognize the assistance of Cristina Alves dos Santos
and Melania Ruiz of Springer.
ix
Contributors
Kenneth C. Anderson
The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology,
Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
Shani Bialik
Department of Molecular Genetics, Weizmann Institute of Science, Rehovot,
Israel 76100
Octavian Bucur
Department of Pathology, Harvard Medical School, Beth Israel Deaconess
Medical Center, 99 Brookline Avenue, Boston, MA 02215, USA
Anas Chalah
Department of Pathology, Harvard Medical School, Beth Israel Deaconess
Medical Center, 99 Brookline Avenue, Boston, MA 02215, USA
Dharminder Chauhan
The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology,
Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
Dipanjan Chowdhury
CBR Institute for Biomedical Research and Department of Pediatrics,
Harvard Medical School, 200 Longwood Avenue, Boston, MA 02115, USA
Victoria Del Gaizo Moore
Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA
Jui Dutta
Center for Advanced Biotechnology and Medicine; Graduate Program in
Biochemistry and Molecular Biology, Robert Wood Johnson Medical School,
University of Medicine and Dentistry of New Jersey, Piscataway, NJ 08854-5638,
USA
Derek M. Dykxhoorn
CBR Institute for Biomedical Research and Department of Pediatrics,
Harvard Medical School, 200 Longwood Avenue, Boston, MA 02115, USA
xi
xii Contributors
Wafik S. El-Deiry
Laboratory of Molecular Oncology and Cell Cycle Regulation, Departments of
Medicine (Hematology/Oncology), Genetics, and Pharmacology, The Institute
for Translational Medicine and Therapeutics and the Abramson Comprehensive
Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, PA
Gaofeng Fan
Center for Advanced Biotechnology and Medicine; Graduate Program in
Biochemistry and Molecular Biology, Robert Wood Johnson Medical School,
University of Medicine and Dentistry of New Jersey, Piscataway,
NJ 08854-5638, USA
Yongjun Fan
Center for Advanced Biotechnology and Medicine, Robert Wood Johnson
Medical School, University of Medicine and Dentistry of New Jersey,
Piscataway, NJ 08854-5638, USA
Céline Gélinas
Center for Advanced Biotechnology and Medicine; Department of Biochemistry
and Cancer Institute of New Jersey, Robert Wood Johnson Medical School,
University of Medicine and Dentistry of New Jersey, Piscataway,
NJ 08854-5638, USA
Alexandra R. Grassian
Department of Pathology, Harvard Medical School, Beth Israel Deaconess
Medical Center, 99 Brookline Avenue, Boston, MA 02215, USA
Nupur Gupta
Center for Advanced Biotechnology and Medicine; Graduate Program in
Biochemistry and Molecular Biology, Robert Wood Johnson Medical School,
University of Medicine and Dentistry of New Jersey, Piscataway,
NJ 08854-5638, USA
Wendy Halpern
Human Genome Sciences, Pathology, Pharmacokinetics and Toxicology,
Rockville, MD 20850, USA
Peter Hersey
Immunology and Oncology Unit, Newcastle Mater Hospital, Newcastle,
NSW 2300, Australia
Teru Hideshima
The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology,
Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
Robin C. Humphreys
Human Genome Sciences, Development Sciences and Research, Rockville,
MD 20850, USA